DeepIntent Secures $637M Investment from Vitruvian Partners to Accelerate AI-Driven Transformation of Healthcare Marketing
Funding will accelerate DeepIntent’s next phase of growth, product development, and industry leadership – empowering clients with smarter marketing solutions
NEW YORK — September 9, 2025 — DeepIntent, Inc. (“DeepIntent”), the leading healthcare demand-side platform (DSP), today announced a strategic investment of $637 million from Vitruvian Partners, a global investment firm specializing in high-growth technology leaders. The investment will accelerate DeepIntent’s next phase of expansion and product innovation—enhancing its platform with new generative AI capabilities and integrations that improve patient outcomes through the use of real-world data, real-time advertising, and data science.
The company’s continued evolution will build on its proprietary software platform, powered by Health Intelligence™, which unifies media, clinical data, and AI to drive more meaningful engagement between life sciences brands, healthcare providers (HCPs), and patients.
“We see a tremendous opportunity to build on our platform’s success by integrating breakthrough technologies that will reshape how healthcare marketers engage and educate their audiences,” said Chris Paquette, founder and CEO of DeepIntent. “Data-driven digital advertising has already transformed our clients’ ability to bring innovative therapeutics to market faster and more efficiently. We believe that recent advancements in generative AI and real-world data will enable a new level of precision – delivering highly personalized brand experiences by unifying the industry’s most comprehensive data and premium media within a single, integrated platform. We’re excited to partner with Vitruvian to bring this next chapter of our company – and our industry – to life in the coming quarters.”
Since its founding in 2016, DeepIntent has led the digital transformation of healthcare marketing with a category-defining platform that connects brands with healthcare providers (HCPs), patients and health consumers across the United States. Today, DeepIntent powers campaigns for hundreds of brands—including 19 of the top 20 global life sciences companies and their agencies—by serving as the connective software that enables high-impact engagement with HCPs and patients across digital channels, including streaming TV, podcasts, point-of-care media, and more.
A recent study by MAGNA Media Trials and DeepIntent revealed the immense role that these campaigns play in promoting health education while encouraging proactive care, including:
- 92% of healthcare providers say advertising increases patient awareness of available treatments.
- 55% of patients report discovering a previously unknown health condition after seeing a pharmaceutical ad—a figure that rises to 67% in communities with limited access to care.
With the backing of Vitruvian Partners, DeepIntent plans to rapidly expand and scale its offerings, while continuing to build out its marketplace of strategic data and media partners. Clients will gain early and enhanced access to next-generation Health Intelligence™ – helping their brands reach verified HCP and patient audiences with greater precision, improve campaign performance dynamically, and stand out in an increasingly competitive healthcare landscape.
“We’re thrilled to be partnering with visionary founder and CEO of DeepIntent, Chris Paquette, and the exceptional team he’s built,” said Sophie Bower-Straziota, Partner at Vitruvian Partners. “DeepIntent sits at the forefront of powerful structural growth drivers, including the rise of personalized, patient-centered healthcare and the growing availability of data and machine learning to enable more meaningful connections with relevant audiences. We’re excited to support the team in their rapid scaling and accelerating their positive impact across the healthcare ecosystem.”
The transaction represents a new chapter for DeepIntent, with Vitruvian acquiring a majority interest in the company. DeepIntent will continue to operate independently under the leadership of its founder and CEO, Chris Paquette. As part of the transaction, DeepIntent’s Board of Directors will be reconstituted to include a select group of industry leaders and domain experts, bringing deep experience in healthcare, technology, and data-driven marketing to help guide the company’s next phase of growth.
Evercore served as the exclusive financial advisor and Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel to DeepIntent on the transaction. Vitruvian was advised by Canaccord Genuity, Houlihan Lokey, Kirkland & Ellis, Bain & Company, FTI Consulting, Epstein Becker & Green, and Crosslake.
About DeepIntent
DeepIntent is the leading healthcare demand-side platform (DSP), purpose-built to help marketers plan, activate, and optimize data-driven campaigns with speed and precision. Trusted by the world’s top healthcare brands and their agencies, DeepIntent uniquely unites media, identity, and real-world clinical data to power privacy-safe, omnichannel marketing across every screen. Backed by patented technology and proven outcomes, DeepIntent’s platform delivers measurable audience quality and script lift at scale. Learn more at www.deepintent.com.
About Vitruvian Partners
Vitruvian Partners is a global growth-focused investor with offices across London, Miami, San Francisco, Stockholm, Munich, Madrid, Luxembourg, Mumbai, Singapore, and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across asset-light industries. Vitruvian has over $20 billion of active funds which have backed many global winners and leaders in their sectors, including CRF Health, Medison Pharma, Just Eat, EasyPark, Skyscanner, Wise, Global-e, CFC, and Darktrace. Further information can be found at www.vitruvianpartners.com.
Media Contact:
DeepIntent Press
Press@Deepintent.com
